

Date: 5th May, 2025

To,

The Manager,

Department of Corporate Services,

BSE Limited

P. J. Towers, Dalal Street,

Fort, Mumbai – 400 001

Scrip Code: 533573

To,

The Manager,

Listing Department,

National Stock Exchange of India Ltd.

'Exchange Plaza', Bandra Kurla Complex, Bandra

(E), Mumbai – 400 051

NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations, 2015")

Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a specimen copy of the Notice sent to shareholders to claim their Equity Shares which otherwise are liable to get transferred to Investor Education and Protection Fund (IEPF) pursuant to Section 124(6) of the Companies Act, 2013.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,


For Alembic Pharmaceuticals Limited

Manisha Saraf Company Secretary

Encl: A/a

ALEMBIC PHARMACEUTICALS LIMITED

CIN: L24230GJ2010PLC061123



Tel.: +91 265 6637000

Website: www.alembicpharmaceuticals.com; Email Id: apl.investors@alembic.co.in

To 5th **May, 2025**

Name & Address of Shareholder

By Speed Post.

Dear Shareholder,

Ref: DP ID Client ID/ Folio No.:

No. of shares held:

Sub: Transfer of shares in respect of which dividend has not been claimed for seven

consecutive years or more to Investor Education and Protection Fund

We would like to inform you that pursuant to the provisions of Section 124(6) of the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Auditing, Transfer and Refund) Rules, 2016, shares on which dividend has not been encashed or claimed for seven consecutive years or more, are liable to be transferred to the Investor Education and Protection Fund (IEPF), a fund constituted by the Government of India under Section 125 of the Companies Act, 2013.

It has been noticed that you have not encashed the dividend warrants for last seven consecutive years commencing from the unpaid Dividend for the year 2017-2018 on the equity shares held by you as detailed herein above.

The details of dividend amount not claimed by you are as under:

| Dividend for the Financial Year | Dividend Amount (Rs.) | No. of shares held as on Record Date for the concerned financial year. |
|--|-----------------------|--|
| 2017-2018 | | |
| 2018-2019 | | |
| Interim 2019-2020 | | |
| 2020-2021 | | |
| Interim 2021-2022 | | |
| 2022-2023 | | |
| 2023-2024 | | |
| No. of shares liable to be transferred to IEPF Account | | |

The unclaimed dividend(s) for periods prior to the year(s) mentioned above has already been transferred to the IEPF, as required under Section 124(5) of the said Act.

The unclaimed shares and corresponding dividend thereon, which has been or will be transferred to IEPF Authority's Account can be claimed back by the shareholders from IEPF Authority, by filing web form No. IEPF-5.

To claim above unpaid dividend or in case you need any information/clarification, please write to or contact our Registrar and Share Transfer Agents ("RTA"), M/s. MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited), "Geetakunj", 1 Bhakti Nagar Society, Behind ABS Tower, Old Padra Road, Vadodara – 390015, Tel: +91 265 3566768, E-mail Id: vadodara@in.mpms.mufg.com

In case, you are holding your shares in physical form and your KYC details are not yet registered i.e. PAN, Address with PIN code, Email Id, Mobile No., Bank Account details, Specimen Signature & Nomination then, please submit relevant Forms for registering/changing KYC details and Nomination viz., Forms ISR-1, ISR-2, ISR-3, SH-13 and SH-14. These forms are available on website of the Company at https://alembicpharmaceuticals.com/investor-related-forms/ and RTA at https://in.mpms.mufg.com/ >> Resource >> Download >> General >> Format of KYC.

You are requested to claim unpaid dividend on or before 10/08/2025, failing which the above referred shares will be transferred to IEPF.

Thanking you,

Yours faithfully, For Alembic Pharmaceuticals Limited Sd/-Manisha Saraf Company Secretary & Compliance Officer